Chronic migraine evolution after 3 months from erenumab suspension: real-world-evidence-life data.

Simona GuerzoniBaraldi CarloUmberto PensatoValentina FavoniFlavia Lo CastroMaria Michela CainazzoSabina CevoliLuca Pani

Published in: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2022)

Patients affected by CM and MOH at the baseline displayed a significant worsening of their headaches after erenumab discontinuation.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
electronic health record
machine learning
patient reported outcomes
drug induced